Edgar Filing: CARACO PHARMACEUTICAL LABORATORIES LTD - Form 4

CARACO PHARMACEUTICAL LABORATORIES LTD

Form 4

October 09, 2002

OMB APPROVAL

OMB Number: 3235-0287

Expires: January 31, 2005

Estimated average burden hours per response...0.5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 4

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

O Check this box if no longer subject to Section 16.
Form 4 or Form 5 obligations may continue.
See Instruction 1(b).

Name and Address of Reporting Person*	2.	Issuer Name and Ticker or Trading Symbol		I.R.S. Identification Number of Reporting Person, if an entity (Voluntary)	
Joliat, Jay F		Caraco Pharmaceutical Laboratories (CARA)			
(Last) (First) (Middle)		(0.110.2)			
36801 Woodward Avenue Suite 301	4.	Statement for Month/Day/Year	5.	If Amendment, Dat (Month/Day/Year)	e of Original
(Street)		10/8/2002			
	6.	Relationship of Reporting Person(s) to Issuer (Check All Applicable)	7.	Individual or Joint/ (Check Applicable L	
Birmingham, MI 48009 USA		X Director X 10% Owner		X	Form Filed by One Reporting Person
(City) (State) (Zip)		Officer (give title below)		0	Form Filed by More than One Reporting
		Other (specify below)			Person

Edgar Filing: CARACO PHARMACEUTICAL LABORATORIES LTD - Form 4

Reminder:	Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, <i>see</i> instruction 4(b)(v).

Title of 2. Security (Instr. 3)	Transaction 2 Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction 4 Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5.Amount of Sec- urities Beneficially Owned Following Reported Trans- action(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code V	Amount	(A) or (D)	Price			
Common Stock	10/8/2002		P	3,600	A	\$1.80	2,032,454	I	Trust
Preferred Stock							285,714	I	Trust
				Page 2					

Table II Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)							
Title of Derivative Security (Instr. 3)	e 2. Conversion or Exercise 3 Price of Derivative Security	Transaction 3 Date (Month/Day/Year)	A. Deemed Execution 4. Date, if any (Month/Day/Year)	Transaction 5. Code (Instr. 8)		(A) or Disp	e Securities osed of (D)
				Code V	(A)	(D)	
Option							
Option/Warrant							
Option/Warrant							
Option/Warrant							
Option/Warrant							
			Page 3				

6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10.Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	
Date Expiration Exercisable Date	Amount or Number of Title Shares				
	Common Stock		6000	D	
	Common Stock		486666	I	Trust
	Common Stock		225000	I	Trust
	Common Stock		250000	I	Trust
	Common Stock		65000	I	Trust
xplanation of Respons	es:				
	/s/ Jennifer Evar	ns	10/9/02		
	**Signature of Repo Person By Jennifer Evans pe Power of Attorney fill with the SEC	r	Date		

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Page 4